Valeant And Salix Agree On Amended Terms To Merger Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Downgrades Salix Pharmaceuticals (SLXP) to Hold; VRX Raised Bid Appears Final
March 18, 2015 7:13 AM EDTJefferies downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Hold with a price target of $173.00 (from $149.00), saying the $173/share raised offer from Valeant Pharma (NYSE: VRX) appears final.
Analyst David Steinberg commented,... More
